Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Hepatitis C Infection

In brief

The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy subjects.

Key facts

Study ID

NCT00557583

Run by

Virobay Inc.

People needed

48

Starts

2007-11-01

Expected to finish

2008-02-01

Last updated by the study team

2013-12-31

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• males and females between 18 and 45 years of age
• screening body mass index between 20 and 29 kg/m2
• in good health with no clinically significant medical conditions
• able to comprehend and willing to sign an informed consent

You may not qualify if…

• history of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome
• anemia or blood donation within 8 weeks of check-in
• plasma donation within 4 weeks of check-in
• history of alcoholism or drug addiction within 1 year prior to check-in
• use of drugs of abuse
• no tobacco-containing products within 6 months of study
• participation of any clinical trial within 30 days
• history or presence of abnormal ECG
• no prescription or over-the-counter medications within 14 days of study and during the study
• history of Gilbert's syndrome

Where it is running

• Covance Clinical Research Unit — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.